All In MedTech

Device Trial Radar · NCT05758506

Developing a Screening Tool for Primary Immunodeficiency Disease (PID) in Pakistan

Last checked: Nov 20, 2026Latest source record: Jul 31, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

200

Actual

Start

Jul 1, 2024

Primary completion

Sep 30, 2024

Study completion Dec 15, 2024

Sponsor

Lead sponsor
PATHAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 7, 2023

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
No
Who can join
All sexes, from 3 months, up to 15 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Case-control diagnostic accuracy study with 130 potential pediatric PID+ (primary immunodeficiency) patients, and 100 age-matched, healthy controls (PID-). The potential PID+ participants will be recruited prospectively through 9 hospitals in Sindh and Punjab states or contacted via the PID surveillance registry developed by AKU Hospital's Polio Excretion in PID study to identify children with primary antibody deficiency (PAD+: a type of PID+); healthy, age-matched PID-participants will be recruited by snowball sampling. At the point of care, health care workers (HCWs) will collect capillary blood samples (0.1mL) to run the PID rapid screening test and reader on potential PID+ participants (identified by exhibiting \>2 of the Jeffrey Modell warning signs) and healthy, age-matched controls. All pediatric study participants will be sent to the hospital lab to have a confirmatory immunology panel (see 4.4.1 Diagnosing PID for the battery of tests) run on a serum/plasma sample to confirm their PID diagnosis (PID+/PAD-, PID+/PAD+, PID-); a 1.5uL aliquot of serum/plasma will simultaneously be used to run a PID rapid screening test by a laboratory technician (LT). HCWs and LTs will be blinded to true PID status. Blood and serum PID rapid screening test results will be compared to the confirmatory immunology panel to determine diagnostic accuracy. All clinical management of study participants will follow the standard of care for PID in Pakistan and will be based upon the immunology panel result. The HCWs and LTs administering the tests will be trained prior to the diagnostic accuracy test (see Objectives below) and will provide feedback on the tool post-training and post-use to assess usability, acceptability, and feasibility of integrating the test and digital reader into tertiary hospitals for the purpose of improved national PID surveillance, improved PID patient care, and polio eradication in Pakistan.

Conditions

  • Primary Immunodeficiency Diseases

Interventions

  • Primary Immunodeficiency (PID) Rapid Diagnostic Test (RDT)Device

    We are evaluating the accuracy of a new rapid diagnostic screening test. There is no medical intervention with the participants in this study.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Diagnostic accuracyTime frame: 8 month
  2. Determine usability, acceptability, feasibility of integrating PID test and digital reader into tertiary hospitals for improved patient careTime frame: 8 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Aga Khan University Hospital

    Karachi, Pakistan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.